iData Insights

Cystic Fibrosis - Pipeline Review, H2 2015 Is Released

Press Release   •   Feb 01, 2016 14:01 IST

This report provides comprehensive information on the therapeutic development for Cystic Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cystic Fibrosis and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Cystic Fibrosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cystic Fibrosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cystic Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Cystic Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cystic Fibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cystic Fibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Browse Complete Report with TOC http://www.idatainsights.com/reports-landing-page.php?id=179097/cystic-fibrosis-pipeline-review-h2-2015

To Get Sample Copy of Report visit http://www.idatainsights.com/reports-landing-page.php?id=179097/cystic-fibrosis-pipeline-review-h2-2015

Table of Contents

Table of Contents 2

List of Tables 8

List of Figures 10

Introduction 11

Global Markets Direct Report Coverage 11

Cystic Fibrosis Overview 12

Therapeutics Development 13

Pipeline Products for Cystic Fibrosis - Overview 13

Pipeline Products for Cystic Fibrosis - Comparative Analysis 14

Cystic Fibrosis - Therapeutics under Development by Companies 15

Cystic Fibrosis - Therapeutics under Investigation by Universities/Institutes 21

Cystic Fibrosis - Pipeline Products Glance 22

Late Stage Products 22

Clinical Stage Products 23

Early Stage Products 24

Unknown Stage Products 25

Cystic Fibrosis - Products under Development by Companies 26

Cystic Fibrosis - Products under Investigation by Universities/Institutes 33

Cystic Fibrosis - Companies Involved in Therapeutics Development 34

Actelion Ltd 34

Akari Therapeutics, Plc 35

Alaxia SAS 36

AlgiPharma AS 37

AmpliPhi Biosciences Corporation 38

Arcturus Therapeutics, Inc 39

Aridis Pharmaceuticals LLC 40

Bayer AG 41

Boehringer Ingelheim GmbH 42

Carolus Therapeutics, Inc. 43

Celtaxsys, Inc. 44

Chiesi Farmaceutici SpA 45

Cilian AG 46

Concert Pharmaceuticals, Inc. 47

Corbus pharmaceuticals, Inc. 48

Cyclacel Pharmaceuticals, Inc. 49

DiscoveryBiomed, Inc. 50

Errant Gene Therapeutics, LLC 51

Galapagos NV 52

GlaxoSmithKline Plc 53

Grifols, S.A. 54

Grupo Praxis Pharmaceutical SA 55

Horizon Pharma Plc 56

Insmed Incorporated 57

Invion Limited 58

JHL Biotech, Inc. 59

Kamada Ltd. 60

La Jolla Pharmaceutical Company 61

Lamellar Biomedical Ltd 62

Laurent Pharmaceuticals Inc. 63

Merck & Co., Inc. 64

Microbion Corporation 65

Mucokinetica Ltd. 66

NanoBio Corporation 67

Nivalis Therapeutics, Inc. 68

Nostrum Pharmaceuticals, LLC 69

Novabiotics Limited 70

Novartis AG 71

OSE Pharma SA 72

Parion Sciences, Inc. 73

Pfizer Inc. 74

Pharmaxis Limited 75

PhaseBio Pharmaceuticals, Inc. 76

Polyphor Ltd. 77

Progenra, Inc. 78

ProQR Therapeutics N.V. 79

Protalix BioTherapeutics, Inc. 80

Proteostasis Therapeutics, Inc. 81

PTC Therapeutics, Inc. 82

Pulmatrix, Inc. 83

ReveraGen BioPharma, Inc. 84

Savara Inc. 85

Serendex Pharmaceuticals A/S 86

Shionogi & Co., Ltd. 87

Shire Plc 88

Synovo GmbH 89

TGV-Laboratories 90

The International Biotechnology Center (IBC) Generium 91

Verona Pharma Plc 92

Vertex Pharmaceuticals Incorporated 93

Xenetic Biosciences plc 94

Zambon Company S.p.A. 95

Cystic Fibrosis - Therapeutics Assessment 96

Assessment by Monotherapy Products 96

Assessment by Combination Products 97

Assessment by Target 98

Assessment by Mechanism of Action 102

Assessment by Route of Administration 105

Assessment by Molecule Type 107

Read More http://www.idatainsights.com/reports-landing-page.php?id=179097/cystic-fibrosis-pipeline-review-h2-2015

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

ContactUs:
iData Insights

Tel: 1-866-237-2965

Web: http://www.idatainsights.com
Email: info@idatainsights.com

AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future project.